TABLE 1

Demographics and main clinical characteristics of the total population of chronic obstructive pulmonary disease (COPD) patients identified in the study, those acutely hospitalised because of any medical condition (including exacerbation of COPD (ECOPD)) and those with a main hospital discharge diagnosis of ECOPD

Total COPD population (n=69 359)All-cause acute hospitalisation of COPD patients (n=26 453)Acute hospitalisations due to ECOPD (n=8331)
Demographics
 Age, years72.9 (72.8–73.0)76.2 (76.1–76.5)77.8 (77.6–78.0)
 Male77.185.188.4
Comorbidities
 Arterial hypertension70.270.973.5
 Dyslipidaemia48.540.742.3
 Heart failure38.838.052.6
 Diabetes37.436.239.2
 Obesity25.417.020.4
 Atrial fibrillation18.717.119.9
 Sleep apnoea17.814.516.5
 Depression13.611.413.0
 Hiatal hernia13.39.910.5
 Ischaemic cardiopathy12.812.313.3
 Pulmonary embolism4.34.75.7
Respiratory treatments
 LAMA81.155.084.6
 LABA/ICS62.545.172.7
 LABA/LAMA37.619.220.3

Data are presented as mean (95% CI) or %. LAMA: long-acting anti-muscarinic antagonists; LABA: long-acting β2-agonists; ICS: inhaled corticosteroids. The percentages of inhaled treatments can add up to more than 100% due to changes in the treatment of some patients during the follow-up period. Most LAMA were administered in association with LABA/ICS (triple therapy).